Boston Scientific Corporation (NYSE:BSX) received a Buy rating from UBS on December 17, with a price target of $140. UBS analyst Danielle Antalffy believes the risk/reward profile for BSX is skewed to the upside heading into 2026, supported by high-growth business areas. CEO Mike Mahoney aims to grow the Electrophysiology (EP) division and WATCHMAN device sales.

UBS predicts a slowdown in the Electrophysiology (EP) division for Boston Scientific Corporation (NYSE:BSX) in 2026, but CEO Mike Mahoney is committed to exceeding market growth rates. The WATCHMAN device, representing 10% of sales, is expected to sustain double-digit growth. UBS sees BSX guiding 2026 sales growth above its long-range target of 10-12%.

Boston Scientific Corporation (NYSE:BSX) is positioned for potential upside in 2026, driven by the WATCHMAN business, according to UBS. The American biotechnology and biomedical engineering company offers therapies for various diseases. While BSX is a sound investment, UBS suggests certain AI stocks may offer greater upside potential and less downside risk.

Investors looking for opportunities beyond Boston Scientific Corporation (NYSE:BSX) may consider AI stocks with significant potential. For more information on AI stock opportunities, check out the free report available. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: UBS Reiterates Buy Rating on Boston Scientific (BSX)